Nativis Appoints Dr. Donna Morgan Murray as Chief Regulatory Officer

Burgeoning Demand for MRI-guided Radiation Therapy Systems Market to Fuel Market Growth Thorough the COVID-19 Crisis Period

The relatively new technology for integrating magnetic resonance imaging (MRI) with radiation therapy is becoming increasingly prevalent, with revenues from the MRI-guided radiation therapy systems market exceeding US$ 220 Mn in 2018, according to a recent study by Fact.MR.

COVID-19 to Substantially Increase the Demand for 3D Printing Medical Devices Market from Key End-use Industry Sectors Unveils Fact.MR

The global 3D printing medical devices market is expected to exceed US$ 1,700 Mn in revenues by 2022-end, according to a recent research by Fact.MR.

DOORwaY-90 Study for SIR-Spheres® Therapy as 1st-line Treatment for Hepatocellular Carcinoma Enrolls First Patient

The study will assess the duration of response (DoR) and objective response rate (ORR) of SIR-Spheres. It is being led by co-principal investigators Cheenu Kappadath, PhD and Dr. Armeen Mahvash.

Chris Rivera, Chief Executive Officer of Nativis notes, “We are very excited to welcome Dr. Donna Morgan Murray as Chief Regulatory Officer to Nativis. Dr. Murray’s extensive professional accomplishments and medical background will provide Nativis with a broad range of experience in worldwide regulatory policy, feasibility and strategy.”  Rivera concluded, “As we develop our technology for the treatment of cancer and other serious diseases, it is critical to consider the regulatory pathway for the Voyager system and develop a comprehensive strategy that will bring us towards regulatory approval.”

Nativis Inc., a clinical stage, bio-electronic life science company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, announced that Dr. Donna Morgan Murray has been appointed as Chief Regulatory Officer, effective immediately.

Murray is a seasoned healthcare professional, author of more than 60 publications in peer-referenced journals, and has served on the board of non-profits and other organizations. Most recently the Head of Global Quality & Regulatory Compliance at Bristol-Meyers Squibb, Murray has held that role since 2014. Prior to that, she was the President of ZymoGenetics Inc., a biotechnology company that discovers, develops, and manufactures protein therapeutics at Bristol-Meyers Squibb. Over the past 20 years, Murray has led and directed regulatory strategy and operations for Bristol-Myers Squibb, CuraGen Corporation, and Procter & Gamble Pharmaceuticals. Murray began her professional career in 1984 as a staff scientist in the Anti-Infective Research Department with Norwich Eaton Pharmaceuticals, Inc., a Procter & Gamble Company.

Murray holds a PhD in Immunology from The University of Texas Health Science Center at Houston, where she conducted research in infectious disease & clinical microbiology. Outside of her professional work, she serves as an officer and member of the board of K9 Crime Stoppers Inc. and was the Chief Operating Officer for Independence Guide Dogs.

Chris Rivera, Chief Executive Officer of Nativis notes, “We are very excited to welcome Dr. Donna Morgan Murray as Chief Regulatory Officer to Nativis. Dr. Murray’s extensive professional accomplishments and medical background will provide Nativis with a broad range of experience in worldwide regulatory policy, feasibility and strategy.”  Rivera concluded, “As we develop our technology for the treatment of cancer and other serious diseases, it is critical to consider the regulatory pathway for the Voyager system and develop a comprehensive strategy that will bring us towards regulatory approval.”

Murray added, “I am very pleased to join Nativis as the Chief Regulatory Officer and look forward to applying my experience in the biopharmaceutical industry toward developing a strong regulatory strategy for the Company’s ulRFE™ technology. I look forward to working to ensure that Nativis is well prepared to meet regulatory requirements and milestones for its unique technology platform and to streamline the regulatory process and help rapidly move forward with the Voyager system.”

spot_img

DON'T MISS

Subscribe to Medical Device News Magazine here.

Related Articles